目次
第1章 経口タンパク質＆ペプチドの世界市場 エグゼクティブサマリー
1.1. 経口タンパク質＆ペプチドの世界市場規模および予測（2022年～2032年）
1.2. 地域別概要
1.3. 分野別概要
1.3.1. 分子別
1.3.2. 薬物クラス別
1.3.3. 治療分野別
1.3.4. 剤型別
1.4. 主要な傾向
1.5. 不況の影響
1.6. アナリストの推奨事項と結論
第2章 世界の経口タンパク質＆ペプチド市場の定義と調査の前提条件
2.1. 調査の目的
2.2. 市場の定義
2.3. 調査の前提条件
2.3.1. 対象と除外
2.3.2. 制限
2.3.3. 供給サイド分析
2.3.4. 需要サイド分析
2.4. 推定方法
2.5. 調査対象年
2.6. 通貨換算レート
第3章 世界の経口タンパク質＆ペプチド市場のダイナミクス
3.1. 市場推進要因
3.1.1. 慢性疾患の増加
3.1.2. 経口投与に対する患者のコンプライアンス
3.1.3. 研究開発における協力関係の増加
3.2. 市場の課題
3.2.1. 処方および安定性の問題
3.2.2. 厳格な規制認可
3.3. 市場の機会
3.3.1. 薬物送達システムの革新
3.3.2. 新興市場への拡大
第4章 世界の経口タンパク質＆ペプチド市場の業界分析
4.1. ポーターのファイブフォース分析
4.1.1. 供給業者の交渉力
4.1.2. 購入業者の交渉力
4.1.3. 新規参入の脅威
4.1.4. 代替品の脅威
4.1.5. 競争上の競合
4.2. PESTEL分析
4.3. 投資機会
4.4. 勝利戦略
4.5. 破壊的トレンド
第5章 分子別の世界経口タンパク質＆ペプチド市場規模および予測（2022年～2032年）
5.1. セグメントダッシュボード
5.2. セマグルチド
5.3. リナクロチド
5.4. カルシトニン
5.5. トロフィネチド
5.6. ボクロスポリン
5.7. プレカナチド

第6章 薬効分類別の世界経口タンパク質＆ペプチド市場規模および予測（2022年～2032年）
6.1. 分類別ダッシュボード
6.2. GLP-1受容体アゴニスト
6.3. GEP（消化管内分泌ペプチド）
6.4. CGRP（カルシトニン遺伝子関連ペプチド）

第7章 治療分野別の世界的な経口タンパク質＆ペプチド市場規模および予測（2022年～2032年）
7.1. 分類別ダッシュボード
7.2. 糖尿病
7.3. 消化器
7.4. 遺伝性疾患

第8章 経口タンパク質＆ペプチドの世界市場規模および予測（2022年～2032年） 剤型別
8.1. セグメントダッシュボード
8.2. 錠剤
8.2.1. 即放性錠剤
8.2.2. 制御放出錠
8.2.3. 口腔内崩壊錠
8.3. カプセル
8.3.1. ゼラチンベースのカプセル
8.3.2. 非ゼラチンカプセル
8.3.3. 液体充填カプセル
8.4. 経口溶液
8.4.1. すぐに飲める溶液
8.4.2. 粉末ベースの経口再構成
第9章 地域別の世界的な経口タンパク質＆ペプチド市場規模および予測（2022年～2032年）
9.1. 北米
9.2. ヨーロッパ
9.3. アジア太平洋
9.4. ラテンアメリカ
9.5. 中東およびアフリカ
第10章 競合情報
10.1. 主要企業のSWOT分析
10.1.1. Novo Nordisk A/S
10.1.2. AbbVie Inc.
10.1.3. Pfizer Inc.
10.2. トップ市場戦略
10.3. 新興企業の分析
第11章 調査プロセス
11.1. 調査の属性
11.2. データ収集と分析

The Global Oral Proteins & Peptides Market is valued at approximately USD 6.03 billion in 2023 and is anticipated to grow at an impressive CAGR of 22.5% over the forecast period 2024-2032, reaching USD 20.37 billion by 2032.

This market encompasses a wide array of proteins and peptides administered orally, offering innovative therapeutic approaches for chronic conditions such as diabetes, gastroenterology disorders, and genetic diseases.

Several factors are driving this market growth, including the rising prevalence of chronic diseases, the enhanced patient compliance associated with oral drug formulations, and increasing collaborations between pharmaceutical giants for R&D. The oral route of administration ensures better patient adherence, significantly improving therapeutic outcomes. Despite these advantages, the market faces challenges related to the stability and formulation of oral proteins and peptides, alongside the stringent regulatory hurdles that new formulations must overcome.

The semaglutide molecule segment holds the largest share in the market. As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide plays a pivotal role in managing type-2 diabetes. Its growing adoption is fueled by its ability to regulate blood sugar levels and appetite, addressing the needs of a significant diabetic population. Additionally, the tablet formulation segment is poised for the highest growth during the forecast period due to its cost-effectiveness, longer shelf life, and stability, which ensure greater scalability and accessibility for commercial production.

Geographically, Europe stands out as the second-largest market for oral proteins and peptides, owing to its favorable regulatory environment, reimbursement policies, and the presence of key players. North America, however, continues to lead due to its robust healthcare infrastructure and ongoing advancements in pharmaceutical research.

The competitive landscape is marked by prominent players such as Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), and AstraZeneca (UK), among others. These companies are actively driving innovation and expanding the availability of oral protein and peptide therapies globally.

The detailed segmentation of the market is as follows:
By Molecule
• Semaglutide
• Linaclotide
• Calcitonin
• Trofinetide
• Voclosporin
• Plecanatide

By Drug Class
• GLP-1 Receptor Agonist
• GEP
• CGRP

By Therapeutic Area
• Diabetes
• Gastroenterology
• Genetic Disorder

By Formulation
• Tablet
• Capsule
• Oral Solution
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years Considered for the Study
• Historical Year: 2022
• Base Year: 2023
• Forecast Period: 2024–2032

Key Takeaways:
• Market Estimates & Forecasts for 10 years (2022–2032).
• Annualized revenue analysis and regional breakdown for each market segment.
• Detailed analysis of geographical landscape with country-level trends.
• Insights into competitive strategies and market innovations.
• Analysis of market drivers, challenges, and opportunities.

Table of Content
Chapter 1. Global Oral Proteins & Peptides Market Executive Summary
1.1. Global Oral Proteins & Peptides Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Molecule
1.3.2. By Drug Class
1.3.3. By Therapeutic Area
1.3.4. By Formulation
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendations & Conclusion
Chapter 2. Global Oral Proteins & Peptides Market Definition and Research Assumptions
2.1. Research Objectives
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply-Side Analysis
2.3.4. Demand-Side Analysis
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Oral Proteins & Peptides Market Dynamics
3.1. Market Drivers
3.1.1. Rising Prevalence of Chronic Diseases
3.1.2. Patient Compliance for Oral Administration
3.1.3. Increased Collaborations for R&D
3.2. Market Challenges
3.2.1. Formulation and Stability Issues
3.2.2. Stringent Regulatory Approvals
3.3. Market Opportunities
3.3.1. Innovations in Drug Delivery Systems
3.3.2. Expansion into Emerging Markets
Chapter 4. Global Oral Proteins & Peptides Market Industry Analysis
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
4.3. Investment Opportunities
4.4. Winning Strategies
4.5. Disruptive Trends
Chapter 5. Global Oral Proteins & Peptides Market Size & Forecasts by Molecule (2022–2032)
5.1. Segment Dashboard
5.2. Semaglutide
5.3. Linaclotide
5.4. Calcitonin
5.5. Trofinetide
5.6. Voclosporin
5.7. Plecanatide

Chapter 6. Global Oral Proteins & Peptides Market Size & Forecasts by Drug Class (2022–2032)
6.1. Segment Dashboard
6.2. GLP-1 Receptor Agonist
6.3. GEP (Gastrointestinal Endocrine Peptides)
6.4. CGRP (Calcitonin Gene-Related Peptide)

Chapter 7. Global Oral Proteins & Peptides Market Size & Forecasts by Therapeutic Area (2022–2032)
7.1. Segment Dashboard
7.2. Diabetes
7.3. Gastroenterology
7.4. Genetic Disorders

Chapter 8. Global Oral Proteins & Peptides Market Size & Forecasts by Formulation (2022–2032)
8.1. Segment Dashboard
8.2. Tablet
8.2.1. Immediate-Release Tablets
8.2.2. Controlled-Release Tablets
8.2.3. Orally Disintegrating Tablets
8.3. Capsule
8.3.1. Gelatin-Based Capsules
8.3.2. Non-Gelatin Capsules
8.3.3. Liquid-Filled Capsules
8.4. Oral Solution
8.4.1. Ready-to-Drink Solutions
8.4.2. Powder-Based Oral Reconstitution
Chapter 9. Global Oral Proteins & Peptides Market Size & Forecasts by Region (2022–2032)
9.1. North America
9.2. Europe
9.3. Asia Pacific
9.4. Latin America
9.5. Middle East & Africa
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Novo Nordisk A/S
10.1.2. AbbVie Inc.
10.1.3. Pfizer Inc.
10.2. Top Market Strategies
10.3. Emerging Players Analysis
Chapter 11. Research Process
11.1. Research Attributes
11.2. Data Collection and Analysis

❖ 掲載企業 ❖

Novo Nordisk A/S (Denmark)、AbbVie Inc. (US), Pfizer Inc. (US)、AstraZeneca (UK)など

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer